Galapagos NV (GLPG) Stock Analysis
Healthcare · Biotechnology
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at... Read more
TrendMatrix rates Galapagos NV (GLPG) as Hold with moderate confidence. The stock trades at $30.63 with +10.2% upside to the $33.73 price target. Overall score: 6.4/10 across 10 analysis dimensions. Reward/risk ratio: 1.7:1.
Passes 2/4 gates (clean insider activity, no SEC red flags). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Galapagos NV (GLPG) as Hold with moderate confidence. Score 6.4/10.
Take-profit target: $33.73 (+10.2% upside). Reward/risk ratio: 1.7:1. Stop-loss: $28.79.
Analyst target reached - limited upside remaining; Negative momentum; Below 200-day MA.
Galapagos NV trades at a P/E of N/A (forward -37.0). TrendMatrix value score: 9.1/10. Verdict: Hold.
18 analysts cover GLPG with a consensus score of 2.6/5. Average price target: $33.
What does Galapagos NV do?Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United...
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.